GSK's Oncology Gamble Could Rewrite Its Entire Future

The Supporting Cast

Mo-rez isn't working alone. GSK's oncology pipeline reads like a roster built through both internal development and smart acquisitions:

Dostarlimab (an anti-PD-1 antibody, which basically teaches immune cells to recognize and attack cancer) is in a Phase 3 trial in colon cancer.

Niraparib (a PARP inhibitor that blocks a cancer cell's ability to repair its own DNA) is being tested in a Phase 2 trial for glioblastoma, one of the most aggressive brain cancers.

Add in earlier-stage assets targeting multiple myeloma, solid tumors, and various combinations of immunotherapy agents, and you've got a pipeline that covers a wide swath of oncology.

Why This Is Harder Than It Looks

The oncology market isn't exactly lacking for competition. GSK is walking into a cage match with some of the biggest, best-funded cancer franchises in pharma.

AstraZeneca holds roughly 12% market share in small molecule targeted cancer therapies, followed by Bristol-Myers Squibb and Eli Lilly at 7% each. Pfizer, freshly armed with its $43 billion Seagen acquisition from 2023, is building one of the most formidable ADC pipelines in the industry. And Merck's Keytruda remains the single most dominant cancer drug on the planet.

GSK doesn't currently appear in the top tier of oncology market share rankings. This is a company trying to break into an exclusive club where membership requires billions in R&D spending, years of clinical data, and, frankly, some luck.

The Miels Factor

Luke Miels isn't a typical pharma CEO. He joined GSK in 2017 as President of Global Pharmaceuticals after bouncing through leadership roles at AstraZeneca, Sanofi (where he led the Sanofi-Aventis merger), and Roche. He ran businesses across Asia Pacific, Europe, and the US before being named CEO designate in 2025.

His background is commercial, not scientific. That matters. Miels thinks in terms of launches, market positioning, and competitive intensity. Since his appointment, GSK's stock has surged roughly 50%, a clear sign that investors trust his instinct for bold, product-centric decision-making.

His strategy is less about discovering novel biology (though GSK does plenty of that) and more about identifying the right assets, accelerating them through trials, and getting them to market faster than competitors expect.

The Real Question

Can a company historically known for respiratory drugs and vaccines genuinely become a top-tier oncology player? The history of pharma is littered with companies that tried to pivot into cancer and got burned. It's expensive. It's crowded. The science is brutally unforgiving.

But GSK has a few things working in its favor. The oncology business is already growing at 43% annually, providing real revenue (not just pipeline promises). Mo-rez's early data is competitive with best-in-class ADCs. And Miels has demonstrated a willingness to move fast, kill what isn't working, and double down on winners.

The next 12 to 18 months will tell us whether this is a genuine transformation or an expensive aspiration. Five Phase 3 readouts for a single drug is a lot of shots on goal. If even two or three hit, GSK's oncology franchise could go from "emerging" to "formidable" in a single year.

For a company that spent the better part of a decade being politely ignored by oncology investors, that would be quite the comeback story.

Erasca Hit a Home Run. The Stock Fell 47%.

Erasca's pan-RAS inhibitor posted jaw-dropping early cancer data that analysts called a "home run." Then the stock fell 42% in a single day. A patient death, a patent fight, and transparency questions collided with the best data in Erasca's history.